Educational content on VJNeurology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

ACTRIMS 2023 View overview page

1:24
TSPO-PET imaging in MS clinical trials and treatment decisions
Laura Airas • 16 Feb 2023
5:27
CSF immune cell phenotyping & NfL to measure inflammatory activity and DMT response in MS
Shane Arsenault • 20 Feb 2023
3:08
Switching from S1Ps or HETs to DRF: results from the EVOLVE-MS-1 study
Barry Singer • 28 Feb 2023
2:53
Future studies on damaging pathways associated with MS progression & severity
Peter Kosa • 28 Feb 2023
3:32
Blood biomarkers of disease activity in MS
Shane Arsenault • 20 Feb 2023
1:13
Longitudinal studies to bring sNfL to MS clinical practice
Elias Sotirchos • 27 Feb 2023
4:02
The effects of myelin loss and remyelination on visual cortical function
Gustavo Della Flora Nunes • 20 Feb 2023
7:58
Molecular mechanisms associated with MS progression, severity and phenotype
Peter Kosa • 28 Feb 2023
2:15
Role of oligodendrocytes in demyelination & remyelination in MS: future research
Gustavo Della Flora Nunes • 20 Feb 2023
1:14
EBV & MS risk at ACTRIMS
Anibal Chertcoff • 27 Feb 2023
1:31
GFAP: a potential biomarker for progression in MS
Elias Sotirchos • 27 Feb 2023
2:59
The development of clinically useful biomarkers in MS
Shane Arsenault • 20 Feb 2023
3:27
Research on the visual system and MS
Gustavo Della Flora Nunes • 20 Feb 2023
2:34
Improving comprehensive MS care through innovative and specialized approaches
Barry Singer • 28 Feb 2023
2:30
Four-year efficacy and safety of evobrutinib for relapsing MS
Emily Evans • 21 Feb 2023
1:43
Progressive MS: emerging treatments
Emily Evans • 21 Feb 2023
The content of VJNeurology is intended for healthcare professionals